Regencell Bioscience Holdings (RGC) Share-based Compensation (2023 - 2025)
Regencell Bioscience Holdings' (RGC) quarterly Share-based Compensation came in at $24.5 million in Q2 2025, up 2961.28% quarter-over-quarter from $800008.0 in Q2 2023.
Powered by 
Analysis
Regencell Bioscience Holdings (RGC) Share-based Compensation (2023 - 2025) Analysis & Trends
Regencell Bioscience Holdings (RGC) has reported Share-based Compensation for 2 consecutive years, with $24.5 million the latest figure, recorded in Q2 2025.
- For the quarter ending Q2 2025, Share-based Compensation changed N/A year-over-year to $24.5 million; the trailing twelve-month figure through Jun 2025 stood at $24.5 million (changed N/A YoY), and the FY2025 full-year result was $24.5 million, up 5350.68% from the prior year.
- Share-based Compensation climbed to $24.5 million in Q2 2025 per RGC's latest filing, from $800008.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $24.5 million in Q2 2025 and bottomed at $800008.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.53 Bn | 625.77 Bn | 17.26 Bn | -950.00 Mn |
| 2 | AbbVie | 442.27 Bn | 435.70 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 366.81 Bn | 359.67 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.37 Bn | 147.67 Bn | 10.94 Bn | 249.00 Mn |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.12 Bn | 44.12 Bn | - | 277.20 Mn |
| 8 | Incyte | 25.49 Bn | 20.95 Bn | 1.57 Bn | 67.26 Mn |
| 9 | United Therapeutics | 21.55 Bn | 18.89 Bn | 683.80 Mn | 19.00 Mn |
| 10 | Regencell Bioscience Holdings | 75.87 Mn | 73.51 Mn | - | - |